Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Axial Spondyloarthritis. According to GlobalData, Phase III drugs for Axial Spondyloarthritis have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ivarmacitinib sulfate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ivarmacitinib sulfate overview
SHR-0302 (ARQ-250) is under development for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, axial spondyloarthritis, ulcerative colitis, psoriatic arthritis, moderate to severe atopic dermatitis, vitiligo,hand eczema, alopecia areata and other inflammatory dermatoses. The drug candidate is administered orally and topically and formulated as tablet and cream. It acts by targeting JAK1 (Janus Kinase 1).
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Ivarmacitinib sulfate’s drug-specific PTSR and LoA scores, buy the report here.